BioSpace News Archive

K36 Therapeutics, Inc. announced today its $30 million Series A financing co-led by F-Prime Capital and Atlas Venture with Eight Roads Ventures.

Marker Therapeutics, Inc. today announced the appointment of Katharine Knobil , M.D., to the Company’s Board of Directors.

4D pharma Presents Microbiome Analyses from Phase II Clinical Trial of Blautix ® for IBS-C and IBS-D at Gastro 2021.

Board of Directors Approves Plans to Initiate Quarterly Cash Dividend and Authorizes $2.5 Billion Share Repurchase Program.

Infinity BiologiX (“IBX”), a leader in analytics, bioprocessing and biobanking, help identify first case of Omicron in Minnesota.

AIM ImmunoTech Inc. (NYSE American: AIM) today announced that safety data on its drug Ampligen was recently presented at the Eighth European Scientific Working Group on Influenza (ESWI) virtual conference in Salzburg, Austria, on December 4-7, 2021.

Innate Pharma SA announced that data from the Phase 2 expansion cohort, exploring the triplet combination of monalizumab, cetuximab and durvalumab in the first-line treatment of patients with recurrent or metastatic head and neck squamous cell cancer, will be presented virtually at the ESMO Immuno-Oncology Congress 2021.

Quercis Pharma AG announced that it has signed an Agreement with GEM Global Yield LLC SCS, the Luxembourg based private alternative investment group, to provide Quercis with a share subscription facility of up to USD 150 million for a 36-month term following a public listing.

Alloy Therapeutics, a biotechnology ecosystem company, announced it has acquired deepCDR Biologics, a Basel, Switzerland-based developer of deep learning technology for antibody discovery and optimization.

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the course of autoimmune disease, today announced positive topline results from the AURORA 2 continuation study evaluating the long-term safety and tolerability of LUPKYNIS™.